REG - Marshall Wace LLP Takeda Pharma.Co.Ltd - Form 8.3 - Takeda Pharmaceutical Co Ltd
RNS Number : 7507LMarshall Wace LLP28 December 2018FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser:
Marshall Wace LLP (on behalf of itself and its affiliates)
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:
Use a separate form for each offeror/offeree
Takeda Pharmaceutical Company Limited
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:
For an opening position disclosure, state the latest practicable date prior to the disclosure
27 Dec 2018
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
YES
If YES, specify which:
Shire plc
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security:
Ordinary shares (ISIN: JP3463000004) - interest and short positions partially held via ADSs (ISIN: US8740602052)
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled:
1,862,975
0.24%
806,877
0.10%
(2) Cash-settled derivatives:
1,085,072
0.14%
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:
1,862,975
0.24%
1,891,949
0.24%
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
Ordinary Shares
Purchase
17,400
JPY 3817.5
Ordinary Shares
Sale
16,800
JPY 3817.5
Ordinary Shares
Sale
96
JPY 3808
Ordinary Shares
Sale
5,707
JPY 3821.7043
Ordinary Shares
Sale
5,213
JPY 3831.1663
Ordinary Shares
Sale
883
JPY 3833.3647
Ordinary Shares
Sale
250,570
JPY 3820.816
Ordinary Shares
Sale
804
JPY 3833.7463
Ordinary Shares
Sale
37,691
JPY 3848.9521
Ordinary Shares
Sale
11,599
JPY 3838.1408
Ordinary Shares
Sale
5,563
JPY 3840.213
Ordinary Shares
Sale
7,368
JPY 3793.1005
Ordinary Shares
Sale
1,751
JPY 3793.2283
Ordinary Shares
Sale
3,870
JPY 3801.1918
Ordinary Shares
Sale
10,585
JPY 3808.9517
Ordinary Shares
Sale
2,891
USD 33.52
Ordinary Shares
Purchase
2,891
USD 33.52
Ordinary Shares
Sale
212
USD 33.04
ADS
Sale
2,751
USD 16.885
ADS
Sale
588
USD 16.885
ADS
Purchase
3,339
USD 16.885
ADS
Sale
1,764
USD 16.776667
ADS
Sale
560
USD 16.776667
ADS
Sale
376
USD 16.776667
ADS
Sale
146
USD 16.717143
ADS
Sale
98
USD 16.717143
ADS
Sale
456
USD 16.717143
ADS
Sale
166
USD 16.6875
ADS
Sale
523
USD 16.6875
ADS
Sale
111
USD 16.6875
ADS
Sale
1,558
USD 16.77453
ADS
Sale
333
USD 16.77453
ADS
Sale
496
USD 16.77453
ADS
Sale
427
USD 16.748037
ADS
Sale
2,004
USD 16.748037
ADS
Sale
636
USD 16.748037
ADS
Sale
1,454
USD 16.7598
ADS
Sale
312
USD 16.7599
ADS
Sale
464
USD 16.7598
(b) Cash-settled derivative transactions
Class of relevant security
Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities
Price per unit
Ordinary Shares
CFD
Reducing a long position
25,800
JPY 3817.5
Ordinary Shares
CFD
Reducing a short position
25,800
JPY 3817.5
Ordinary Shares
CFD
Reducing a long position
600
JPY 3817.5
Ordinary Shares
CFD
Reducing a long position
4
JPY 3808
Ordinary Shares
CFD
Reducing a long position
93
JPY 3821.865164
Ordinary Shares
CFD
Reducing a long position
87
JPY 3829.654288
Ordinary Shares
CFD
Reducing a long position
17
JPY 3822.878151
Ordinary Shares
CFD
Reducing a long position
7,630
JPY 3818.433357
Ordinary Shares
CFD
Reducing a long position
196
JPY 3822.795918
Ordinary Shares
CFD
Reducing a long position
1,009
JPY 3835.773555
Ordinary Shares
CFD
Closing a long position
264
JPY 3815.237834
Ordinary Shares
CFD
Increasing a short position
2,637
JPY 3815.237834
Ordinary Shares
CFD
Increasing a short position
2,437
JPY 3816.124397
Ordinary Shares
CFD
Increasing a short position
532
JPY 3802.134549
Ordinary Shares
CFD
Increasing a short position
249
JPY 3802.237808
Ordinary Shares
CFD
Increasing a short position
930
JPY 3812.352361
Ordinary Shares
CFD
Increasing a short position
95,215
JPY 3799.150833
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security
Product description e.g. call option
Writing, purchasing, selling, varying etc.
Number of securities to which option relates
Exercise price per unit
Type
e.g. American, European etc.
Expiry date
Option money paid/ received per unit
(ii) Exercise
Class of relevant security
Product description
e.g. call option
Exercising/ exercised against
Number of securities
Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security
Nature of dealing
e.g. subscription, conversion
Details
Price per unit (if applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached?
NO
Date of disclosure:
28 Dec 2018
Contact name:
Matthew Rooney
Telephone number:
020 7316 2253
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRETBSBDDBDDBGII
Recent news on Takeda Pharmaceutical Co
See all newsREG - Malin Corp PLC - Malin Announces 2021 Full Year Results
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Confirmation of post-offer intention statements
AnnouncementREG - Morgan Stanley&CoLLC Takeda Pharma.Co.Ltd - Form 8.5 (EPT/RI) - Replacement of Takeda
AnnouncementREG - Takeda Pharma.Co.Ltd Shire plc - Statement re Applicable Exchange Rate
AnnouncementREG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - Replacement of Takeda
Announcement